Search

This document is a letter published in the journal Clinical Drug Investigation. It presents the results of a pilot study on the impact of long-term treatment with tolvaptan on the quality of life (QoL) of patients with autosomal dominant polycystic kidney disease (ADPKD). The study used the SF-36 questionnaire to assess various aspects of QoL. The results suggest that tolvaptan treatment may improve the perception of physical limitations but worsen vitality and mental health. However, the small sample size and retrospective nature of the study limit the conclusions that can be drawn. Further research is needed to explore the impact of tolvaptan on QoL in ADPKD patients. [Extracted from the article]